A highly effective anti-cancer agent (synthetic Vitamin A analog) in combination with a new drug delivery system, has demonstrated for us a tendency to naturally collect in the pancreas.  Regardless of whether concentration in the pancreas results from passive or active uptake, it appears possible to exploit this new finding to target therapeutics for Pancreatic Carcinoma and stimulate high levels of drug uptake and/or retention at this site.

Since pancreatic cancer is highly resistant to all current, non-invasive therapies, there are only three accepted treatments: surgery, radiation therapy, and chemotherapy. However, even these methods are inadequate as chances of early detection are low, resulting in a 5-9 month survival rate. Considering there is truly no effective drug treatment for pancreatic cancer, our Vitamin A analog drug would potentially be treated as an “Orphan Drug”. This advantageous position, in conjunction with the fact that this analog has previously undergone considerable clinical testing, would grant SciTech a defensible position from which to develop, manufacture, and market this pancreatic cancer drug therapy. With estimates reaching approximately 32,000 pancreatic cancer deaths yearly and virtually no effective alternative treatment available, the market potential is as extremely significant as the need urgent. 

Further developmental opportunity exists beyond this synthetic Vitamin A analog being formulated as a pancreatic cancer drug agent. As multiple, substantiated pancreatic cancer drugs have difficulty targeting the pancreas, the analog in conjunction with our unique IV Retinoid technology could serve as a highly efficient delivery system for current drugs, revolutionizing their effectiveness.